Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Director Rita Jain of Avalo Therapeutics (AVTX) received a stock option grant on June 17, 2025, according to a Form 4 filing. The key details include:
- Granted 40,200 stock options to purchase common stock at an exercise price of $4.47 per share
- Options will vest in three equal installments on the first, second, and third anniversary of the grant date
- Options expire on June 17, 2035
- Vesting is contingent on continued service as director
This equity compensation grant appears to be part of the company's director compensation program. The filing was signed by Donald R. Reynolds via power of attorney on June 18, 2025. This transaction represents a new position for the director, as no prior holdings were reported.